AstraZeneca Pharma India Limited (ASTRAZEN) fair value: what the stock is really worth
We calculate from audited financials what AstraZeneca Pharma India Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.
Compare price with fair valuebelow fair value = cheap, above = expensive
Check the quality50 and up solid, 75 and up strong
Watch it or check another stockalert when fair value or trend changes
Healthcare · IN · Market cap ₹172B (≈ $1.8B) · ISIN INE203A01020
At a glance
APAstraZeneca Pharma India LimitedASTRAZEN · NSE
Price₹6,877
Fair Value₹1,495
Upside−78.3%
Quality58/100
A solid business, but trading 360% above our fair value of ₹1,495.
As of Sep 2, 2026, the fair value of AstraZeneca Pharma India Limited is ₹1,495 per share against a price of ₹6,877, so the fair value sits 78% below the price. A model estimate from reported figures, not an analyst target.
!Expensive Growth (revenue 5y +23.0 %/yr)
!Thin margins · 8.2% net margin
✓generates free cash flow
·0.52% dividend yield
!Trails peers (5/13)
!Moderate moat 49/100
!Weak on dividend: 10 out of 100
Evidence: HighRange ₹770.00 to ₹2,068
Fair value as of: Sep 2, 2026
From 25 valuation models · updated 8 days ago
Share price −15.0% over the past month.
This is the short version. In the app for AstraZeneca Pharma India Limited:
Watch AstraZeneca Pharma India Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceable See the method →
What matters now
The price sits above even our optimistic bull case (₹2,068). The favourable scenario is already priced in.
The model range is unusually wide (₹770.00 to ₹2,068). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 2, 2026.
How to read this chart
60‑month range ₹2,426 – ₹10,474 · fair‑value band ₹770.00 – ₹2,068 · the ₹6,877 price screens above the ₹1,495 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 2, 2026.
AstraZeneca Pharma India Limited (ASTRAZEN) currently trades at ₹6,877, while our model-based Fair Value estimate is ₹1,495, implying the stock looks roughly 360.0% overvalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of ₹1,848 per share, and 0 of the 25 models we run sit above the ₹6,877 price. Bear case: the Growth DCF group reads lowest at ₹220.27, and 25 of the 25 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, AstraZeneca Pharma India Limited generated revenue of ₹22.8B at a net margin of 8.2%. Revenue grew 20.4% year over year. It earns a return on equity of 22.8%. The balance sheet holds a net cash position of ₹3.4B. Fundamentals as of Sep 2, 2026
Scenario range: ₹770.00 (bear) to ₹2,068 (bull), the price of ₹6,877 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 30% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −78%, ASTRAZEN screens richer than that median.
Fair Value models
Based on fiscal year 2026 figures (about 5 months old). Earnings retained since then (₹17.27 per share) are deliberately not added.
Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →
Note: the current price implies far more future growth than the conservative anchors of our models allow (base growth is deliberately capped, we do not regard such extreme rates as sustainable). Our models are not designed for expectations this high; that is why the individual models scatter extremely (₹216.42 to ₹3,054). Read the values as a conservative anchor, not as a price target.
ModelBear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence
Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
P/E ratio92.1
P/S ratio7.59P/E × margin
EPS (TTM)₹74.68price ÷ EPS = P/E 92.1
Dividend yield0.5%payout 48.2%
Net margin8.2%FY2026
Return on equity22.8%TTM
More key figures
Profitability
Return on assets (EBIT)13.0%avg 5y
Operating margin9.6%TTM
Growth
Revenue (TTM)₹22.8BTTM
Revenue growth (YoY)+20.4%3y avg +31.4%
EPS growth (YoY)−23.0%
Balance sheet & cash flow
Free cash flow₹32.1MFY2026
Net cash₹3.4BFY2026
Figures from reported company fundamentals · as of Sep 2, 2026. TTM = trailing twelve months.
Quality Score breakdown
Overall quality58/100
Of which business quality 58
· Market factors (momentum, volatility) 37
Profitability64
Margins and returns on capital today
Quality Growth57
Are margins and returns improving?
Cashflow13
Earnings quality: real cash, not paper profit
Fin. Strength87
Balance sheet, leverage, solvency risk
Investment43
Disciplined investing over empire-building
Low Volatility93
Calm price path (market factor)
Momentum20
Price trend over the last 3–12 months (market factor)
52W Momentum3
Distance to the 52-week high (market factor)
Net Issuance82
Buybacks instead of dilution
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally.
Full company description
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company has a strategic collaboration with Leica Biosystems and Daiichi Sankyo Company, Limited for the development of an immunohistochemistry assay and an image analysis algorithm for the TROP2 NMR biomarker in non-small cell lung cancer. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
AstraZeneca Pharma India Limited reported revenue of ₹22.8B in FY2026 versus ₹8.1B in FY2022, a compound +29.6%/yr. Reported net income was ₹1.9B in FY2026, compounding +32.1%/yr from FY2022.
Growth Quality 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2026)
₹22.8B
Latest YoY
+32.8%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+31.4%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+23.0%
Avg. revenue growth/yr (21Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+12.5%
Value creation/yr (5Y, in INR) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +21.5%
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share+21.0%
Dividend yield0.5%
Trend ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5Y 21.0% vs 10Y 30.9%, flattening
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14.4% (2021) → 10.3% (2026) · falling
Worst earnings drop240% (2013) (loss year, drop beyond 100%) · in INR
⚠ Final year 2026 sits 62% above trend (one-off), rate approximate
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
This stockSector peers
VALUE0· sector 4
FUTURE100· sector 22
PAST91· sector 25
HEALTH0· sector 97
DIVIDEND10· sector 29
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Sep 2, 2026).
Is AstraZeneca Pharma India Limited (ASTRAZEN) overvalued or undervalued?
As of Sep 2, 2026, our model estimates a fair value of ₹1,495 versus a price of ₹6,877, about −78% upside (overvalued).
What is the fair value of ASTRAZEN?
Our model-based fair value for AstraZeneca Pharma India Limited is ₹1,495 (as of Sep 2, 2026), built from audited fundamentals. The current price: ₹6,877.
What is the quality score of ASTRAZEN?
AstraZeneca Pharma India Limited has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AstraZeneca Pharma India Limited (ASTRAZEN)?
Our model-based price target is the fair value of ₹1,495 (as of Sep 2, 2026) from 25 valuation models. Cautious scenario ₹770.00, optimistic scenario ₹2,068. It is a calculation from audited fundamentals, not an analyst target.
What is the AstraZeneca Pharma India Limited stock forecast for 2026?
Our models put fair value at ₹1,495, about −78% upside versus a price of ₹6,877 (overvalued). Cautious scenario ₹770.00, optimistic scenario ₹2,068. The calculation is refreshed regularly with new filings.
What is the revenue of AstraZeneca Pharma India Limited (ASTRAZEN)?
AstraZeneca Pharma India Limited reported trailing-twelve-month revenue of about ₹22.8B (latest available figure, as of Sep 2, 2026).
What is the net profit margin of ASTRAZEN?
The net profit margin of AstraZeneca Pharma India Limited is about 8.2%, meaning it keeps roughly 8.2% of revenue as net income. Based on the latest reported figures.
Does AstraZeneca Pharma India Limited pay a dividend?
AstraZeneca Pharma India Limited currently shows a dividend yield of about 0.52% relative to its recent price (as of Sep 2, 2026).
What is the intrinsic value of AstraZeneca Pharma India Limited (ASTRAZEN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AstraZeneca Pharma India Limited it is ₹1,495 per share (as of Sep 2, 2026), against a price of ₹6,877. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is AstraZeneca Pharma India Limited stock overvalued or undervalued in 2026?
As of Sep 2, 2026, ASTRAZEN trades above its calculated fair value: price ₹6,877, fair value ₹1,495, a gap of about −78% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ASTRAZEN?
No. The price is what the market pays today (₹6,877); the fair value is what the company's own numbers justify (₹1,495). For AstraZeneca Pharma India Limited the two are ₹5,381 per share apart. That gap is exactly why we show both numbers side by side.
How much is AstraZeneca Pharma India Limited worth?
The market values AstraZeneca Pharma India Limited at about ₹172B (market capitalisation, as of Sep 2, 2026). Per share that is ₹6,877; our models calculate a fair value of ₹1,495 per share.
What do the bullish and bearish scenarios say about ASTRAZEN?
Our models span a range for AstraZeneca Pharma India Limited: cautious scenario ₹770.00, base ₹1,495, optimistic ₹2,068 per share (as of Sep 2, 2026, price ₹6,877). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ASTRAZEN?
AstraZeneca Pharma India Limited trades at a price-to-earnings ratio of 92.1 (as of Sep 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹1,495 is built from several models across several years. Other multiples: P/B 24.2, P/S 9.3, EV/EBITDA 78.8.
How solid is the balance sheet of AstraZeneca Pharma India Limited (ASTRAZEN)?
Balance-sheet figures for AstraZeneca Pharma India Limited (as of Sep 2, 2026): return on equity 22.8%. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is ASTRAZEN from its 52-week high?
AstraZeneca Pharma India Limited trades at ₹6,877, about 30% below its 52-week high of ₹9,850 (as of Sep 2, 2026). Distance from the high says nothing about value: that is what the fair value of ₹1,495 is for.
Which stocks are comparable to AstraZeneca Pharma India Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AstraZeneca Pharma India Limited stock attractive at the current price?
The data as of Sep 2, 2026: price ₹6,877, calculated fair value ₹1,495 (−78%), Quality Score 58/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ASTRAZEN calculated?
We run AstraZeneca Pharma India Limited through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹1,495, with the spread shown as a cautious and an optimistic scenario.
Free · no account needed
Watch AstraZeneca Pharma India Limited in the live analysis
One click puts AstraZeneca Pharma India Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
